IMVT — Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 362
- Website: https://immunovant.com
Latest SEC filings for IMVT
- 4 — 2026-10-23
- 10-Q — 2026-08-06
- 8-K — 2026-08-06
- ARS — 2026-07-22
- 10-K — 2026-05-20
- 8-K — 2026-05-20
- 10-Q — 2026-02-06
- 8-K — 2026-02-06
- 424B5 — 2025-12-12
- 8-K — 2025-12-12
Latest IMVT news
- — Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 (GlobeNewswire Inc.)
- — Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm (gurufocus.com)
- — Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm (prnewswire.com)
- — IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law (gurufocus.com)
- — IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law (businesswire.com)
- — Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) (prnewswire_financial)
Educational tool only — not investment advice.